$54.19
+2.41 (+4.65%)
Open$51.90
Previous Close$51.78
Day High$54.49
Day Low$50.76
52W High$55.60
52W Low$28.95
Volume—
Avg Volume932.1K
Market Cap2.60B
P/E Ratio107.19
EPS$0.42
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-19.5% upside
Current
$54.19
$54.19
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 253.79M | 213.47M | 156.14M |
| Net Income | 15.17M | 11.49M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 20.75M | 16.58M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |